Journal of Pharmacological Sciences · 2006 · 13 citations · 12 references
MedicineNeurosciencePharmacologyMolecular PharmacologyNeuropharmacologyPsychopharmacologyLigand BindingMonoamine NeurochemistryNeurotransmitter ReceptorsReceptor PharmacologySerotonergic PharmacologySerotonergic Signaling5-Hydroxytryptamine Receptor PharmacologyAmino Acid AnalysisSerotonin Receptor BindingSerotonin Receptor PharmacologySerotonin Receptor SignalingSerotonin Receptor SubtypesSerotonin Receptors
The purpose of the present study was to examine 5-hydroxytryptamine (5-HT)(2A)-receptor sarpogrelate interactions by site-directed mutagenesis. Based on molecular modeling studies, aspartic acid (Asp)155[3.32] and tryptophan (Trp)151[3.28] in transmembrane helix (TMH) III and Trp336[6.48] in TMH VI of the 5-HT(2A) receptor were found to interact with sarpogrelate. All of these residues were mutated to alanine (Ala). The Asp3.32Ala mutant did not exhibit any affinity for [(3)H]ketanserin, whereas the Trp3.28Ala mutant showed a markedly decrease in the binding affinity for [(3)H]ketanserin (K(d) >10,000 nM). Therefore, it was not possible to find any sarpogrelate affinity to the mutants using [(3)H]ketanserin. The mutation also abolished agonist-stimulated formation of [(3)H]inositol phosphates (IP) in both cases. On the other hand, the Trp6.48Ala mutant showed reduced binding affinity for [(3)H]ketanserin (K(d) 2.0 nM vs 0.8 nM for the wild-type receptor) and had reduced affinity for sarpogrelate (pK(i) value of 5.71 vs 9.06 for the wild-type receptor). The Trp6.48Ala mutant also showed the greatest decrease in sensitivity to sarpogrelate (pK(b) value 8.81 for wild-type and 5.11 for mutant) in inhibiting agonist-stimulated IP formation. These results provide direct evidence that Asp3.32, Trp3.28, and less importantly, Trp6.48 are responsible for the interaction between the 5-HT(2A) receptor and sarpogrelate. In addition, these results support the findings obtained from molecular modeling studies.
12
Kurt Kristiansen, Wesley K. Kroeze, David L. Willins et al. · Journal of Pharmacology and Experimental Therapeutics · 2000 · 117 citations
Kurt Kristiansen, Wesley K. Kroeze, Bryan L. Roth · Molecular Pharmacology · 2000 · 109 citations
Christina Egan, Katharine Herrick‐Davis, Milt Teitler · Journal of Pharmacology and Experimental Therapeutics · 1998 · 94 citations
Medicine, Neuroscience, Pharmacology +17